SLC5A2 and hydrops fetalis: The favourable cardiovascular outcomes observed in HF patients with reduced and preserved ejection fraction by SGLT2 inhibitors in a recent systematic review [93] highlight the therapeutic potential of focusing on PT function in HF management.